Latest polycythemia vera Stories
-- Pacritinib Abstract #LBA7006 also to be Highlighted in the Official ASCO Press Program -- SEATTLE and DEERFIELD, Ill., April 22, 2015 /PRNewswire/ -- CTI BioPharma Corp.
RnRMarketResearch.com adds "Polycythemia Vera - Pipeline Review, H1 2015" to its store.
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp.
- PharmaEssentia and AOP Orphan announce completion of recruitment of the pivotal European Phase III trial PROUD-PV (www.proud-pv.com) to support global marketing of P1101 (Ropeginterferon alfa-2b).
Trial Meets Primary Endpoint in Intent-to-Treat Population SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp.
SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S.
-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp.
MPN Research Foundation will accept the Abbey S.
Following the discovery of the Calreticulin (CALR) mutation, which accounts for the majority of non JAK/MPL mutations in ET and MF patients, Dr.
FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc.
- A person in a secondary role, specifically the second most important character (after the protagonist).